Characterization of PANoptosis-related genes and the immune landscape in moyamoya disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 May 2024
04 May 2024
Historique:
received:
21
11
2023
accepted:
02
05
2024
medline:
5
5
2024
pubmed:
5
5
2024
entrez:
4
5
2024
Statut:
epublish
Résumé
Moyamoya disease (MMD) is a cerebrovascular narrowing and occlusive condition characterized by progressive stenosis of the terminal portion of the internal carotid artery and the formation of an abnormal network of dilated, fragile perforators at the base of the brain. However, the role of PANoptosis, an apoptotic mechanism associated with vascular disease, has not been elucidated in MMD. In our study, a total of 40 patients' genetic data were included, and a total of 815 MMD-related differential genes were screened, including 215 upregulated genes and 600 downregulated genes. Among them, DNAJA3, ESR1, H19, KRT18 and STK3 were five key genes. These five key genes were associated with a variety of immune cells and immune factors. Moreover, GSEA (gene set enrichment analysis) and GSVA (gene set variation analysis) showed that the different expression levels of the five key genes affected multiple signaling pathways associated with MMD. In addition, they were associated with the expression of MMD-related genes. Then, based on the five key genes, a transcription factor regulatory network was constructed. In addition, targeted therapeutic drugs against MMD-related genes were obtained by the Cmap drug prediction method: MST-312, bisacodyl, indirubin, and tropanyl-3,5-dimethylbenzoate. These results suggest that the PANoptosis-related genes may contribute to the pathogenesis of MMD through multiple mechanisms.
Identifiants
pubmed: 38704490
doi: 10.1038/s41598-024-61241-w
pii: 10.1038/s41598-024-61241-w
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10278Subventions
Organisme : Natural Science Foundation of China
ID : 82371296
Informations de copyright
© 2024. The Author(s).
Références
Ihara, M. et al. Moyamoya disease: Diagnosis and interventions. Lancet Neurol. 21, 747–758. https://doi.org/10.1016/S1474-4422(22)00165-X (2022).
doi: 10.1016/S1474-4422(22)00165-X
pubmed: 35605621
Gonzalez, N. R. et al. Adult moyamoya disease and syndrome: Current perspectives and future directions: A scientific statement from the American heart association/American stroke association. Stroke 54, e465–e479. https://doi.org/10.1161/STR.0000000000000443 (2023).
doi: 10.1161/STR.0000000000000443
pubmed: 37609846
Achrol, A. S., Guzman, R., Lee, M. & Steinberg, G. K. Pathophysiology and genetic factors in moyamoya disease. Neurosurg. Focus https://doi.org/10.3171/2009.1.FOCUS08302 (2009).
doi: 10.3171/2009.1.FOCUS08302
pubmed: 19409010
pmcid: 2905646
He, S. et al. Upregulated cytoskeletal proteins promote pathological angiogenesis in moyamoya disease. Stroke https://doi.org/10.1161/STROKEAHA.123.044476 (2023).
doi: 10.1161/STROKEAHA.123.044476
pubmed: 38095120
pmcid: 10453335
Le, T. et al. Knockdown of long noncoding RNA GAS5 reduces vascular smooth muscle cell apoptosis by inactivating EZH2-mediated RIG-I signaling pathway in abdominal aortic aneurysm. J. Transl. Med. 19, 466. https://doi.org/10.1186/s12967-021-03023-w (2021).
doi: 10.1186/s12967-021-03023-w
pubmed: 34781960
pmcid: 8594130
Cao, G. et al. How vascular smooth muscle cell phenotype switching contributes to vascular disease. Cell Commun. Signal. 20, 180. https://doi.org/10.1186/s12964-022-00993-2 (2022).
doi: 10.1186/s12964-022-00993-2
pubmed: 36411459
pmcid: 9677683
Malireddi, R. K. S. et al. Inflammatory cell death, PANoptosis, mediated by cytokines in diverse cancer lineages inhibits tumor growth. Immunohorizons 5, 568–580. https://doi.org/10.4049/immunohorizons.2100059 (2021).
doi: 10.4049/immunohorizons.2100059
pubmed: 34290111
Karki, R. et al. Interferon regulatory factor 1 regulates PANoptosis to prevent colorectal cancer. JCI Insight https://doi.org/10.1172/jci.insight.136720 (2020).
doi: 10.1172/jci.insight.136720
pubmed: 32554929
pmcid: 7406299
Abida, W. et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 5, 471–478. https://doi.org/10.1001/jamaoncol.2018.5801 (2019).
doi: 10.1001/jamaoncol.2018.5801
pubmed: 30589920
Shi, X. et al. Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma. Oncol. Res. 31, 569–590. https://doi.org/10.32604/or.2023.028964 (2023).
doi: 10.32604/or.2023.028964
pubmed: 37415742
pmcid: 10319585
Wei, S., Chen, Z., Ling, X., Zhang, W. & Jiang, L. Comprehensive analysis illustrating the role of PANoptosis-related genes in lung cancer based on bioinformatic algorithms and experiments. Front. Pharmacol. 14, 1115221. https://doi.org/10.3389/fphar.2023.1115221 (2023).
doi: 10.3389/fphar.2023.1115221
pubmed: 36874021
pmcid: 9977813
Li, R., Zhao, M., Sun, M., Miao, C. & Lu, J. Construction and validation of a PANoptosis-related lncRNA signature for predicting prognosis and targeted drug response in thyroid cancer. PeerJ 11, e15884. https://doi.org/10.7717/peerj.15884 (2023).
doi: 10.7717/peerj.15884
pubmed: 37671354
pmcid: 10476615
She, R. et al. Mitochondrial dysfunctions induce PANoptosis and ferroptosis in cerebral ischemia/reperfusion injury: From pathology to therapeutic potential. Front. Cell. Neurosci. 17, 1191629. https://doi.org/10.3389/fncel.2023.1191629 (2023).
doi: 10.3389/fncel.2023.1191629
pubmed: 37293623
pmcid: 10244524
Yan, W. T. et al. Do pyroptosis, apoptosis, and necroptosis (PANoptosis) exist in cerebral ischemia? Evidence from cell and rodent studies. Neural Regen. Res. 17, 1761–1768. https://doi.org/10.4103/1673-5374.331539 (2022).
doi: 10.4103/1673-5374.331539
pubmed: 35017436
pmcid: 8820688
Chung, J. W. et al. Cav-1 (Caveolin-1) and arterial remodeling in adult moyamoya disease. Stroke 49, 2597–2604. https://doi.org/10.1161/STROKEAHA.118.021888 (2018).
doi: 10.1161/STROKEAHA.118.021888
pubmed: 30355208
Fox, B. M., Dorschel, K. B., Lawton, M. T. & Wanebo, J. E. Pathophysiology of vascular stenosis and remodeling in moyamoya disease. Front. Neurol. 12, 661578. https://doi.org/10.3389/fneur.2021.661578 (2021).
doi: 10.3389/fneur.2021.661578
pubmed: 34539540
pmcid: 8446194
Gao, R. et al. Phosphodiesterase 4D contributes to angiotensin II-induced abdominal aortic aneurysm through smooth muscle cell apoptosis. Exp. Mol. Med. 54, 1201–1213. https://doi.org/10.1038/s12276-022-00815-y (2022).
doi: 10.1038/s12276-022-00815-y
pubmed: 35999453
pmcid: 9440214
Watson, E. C., Grant, Z. L. & Coultas, L. Endothelial cell apoptosis in angiogenesis and vessel regression. Cell. Mol. Life Sci. 74, 4387–4403. https://doi.org/10.1007/s00018-017-2577-y (2017).
doi: 10.1007/s00018-017-2577-y
pubmed: 28646366
Tisch, N. & de Ruiz Almodovar, C. Contribution of cell death signaling to blood vessel formation. Cell. Mol. Life Sci. 78, 3247–3264. https://doi.org/10.1007/s00018-020-03738-x (2021).
doi: 10.1007/s00018-020-03738-x
pubmed: 33783563
pmcid: 8038986
Assaf, S. N. et al. Extracranial microvascular complications of moyamoya disease leading to left ventricular systolic dysfunction. J. Med. Cases 14, 88–94. https://doi.org/10.14740/jmc4057 (2023).
doi: 10.14740/jmc4057
pubmed: 37032739
pmcid: 10079364
Nam, T. M., Jo, K. I., Yeon, J. Y., Hong, S. C. & Kim, J. S. Coronary heart disease in moyamoya disease: Are they concomitant or coincidence?. J. Korean Med. Sci. 30, 470–474. https://doi.org/10.3346/jkms.2015.30.4.470 (2015).
doi: 10.3346/jkms.2015.30.4.470
pubmed: 25829816
pmcid: 4366969
Liu, E. et al. Clinical value of the systemic immune-inflammation index in moyamoya disease. Front. Neurol. 14, 1123951. https://doi.org/10.3389/fneur.2023.1123951 (2023).
doi: 10.3389/fneur.2023.1123951
pubmed: 37153657
pmcid: 10157187
Cheng, L. H. et al. Mitochondrial co-chaperone protein Tid1 is required for energy homeostasis during skeletal myogenesis. Stem Cell Res. Ther. 7, 185. https://doi.org/10.1186/s13287-016-0443-8 (2016).
doi: 10.1186/s13287-016-0443-8
pubmed: 27927223
pmcid: 5143475
Lo, J. F. et al. Tid1, a cochaperone of the heat shock 70 protein and the mammalian counterpart of the drosophila tumor suppressor l(2)tid, is critical for early embryonic development and cell survival. Mol. Cell. Biol. 24, 2226–2236. https://doi.org/10.1128/MCB.24.6.2226-2236.2004 (2004).
doi: 10.1128/MCB.24.6.2226-2236.2004
pubmed: 14993262
pmcid: 355836
Silver, P. A. & Way, J. C. Eukaryotic DnaJ homologs and the specificity of Hsp70 activity. Cell 74, 5–6 (1993).
doi: 10.1016/0092-8674(93)90287-Z
pubmed: 8334705
Lo, J. F. et al. Tid1 is required for T cell transition from double-negative 3 to double-positive stages. J. Immunol. 174, 6105–6112. https://doi.org/10.4049/jimmunol.174.10.6105 (2005).
doi: 10.4049/jimmunol.174.10.6105
pubmed: 15879105
Bae, M. K. et al. Tid-1 interacts with the von hippel-lindau protein and modulates angiogenesis by destabilization of HIF-1A. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-03-2735 (2005).
doi: 10.1158/0008-5472.CAN-03-2735
pubmed: 16357183
Trinh Diane, L. N., Elwi, A. N. & Kim, S. W. Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosis. Oncotarget 6, 396–404. https://doi.org/10.18632/oncotarget.174 (2010).
doi: 10.18632/oncotarget.174
Tsaousi, A. et al. Wnt4/beta-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ. Res. 108, 427–436. https://doi.org/10.1161/CIRCRESAHA.110.233999 (2011).
doi: 10.1161/CIRCRESAHA.110.233999
pubmed: 21193738
Zou, Z. G. et al. Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function. Clin. Sci. (Lond) 134, 2019–2035. https://doi.org/10.1042/CS20200827 (2020).
doi: 10.1042/CS20200827
pubmed: 32706027
You, C. et al. RNF213 polymorphism and moyamoya disease: A systematic review and meta-analysis. Neurol. India https://doi.org/10.4103/0028-3886.107927 (2013).
doi: 10.4103/0028-3886.107927
pubmed: 24262454
O’Neill, E. E., Matallanas, D. & Kolch, W. Mammalian sterile 20-like kinases in tumor suppression an emerging pathway. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-05-1453 (2005).
doi: 10.1158/0008-5472.CAN-05-1453
pubmed: 15994916
Avruch, J. et al. Protein kinases of the Hippo pathway: Regulation and substrates. Semin. Cell Dev. Biol. 23, 770–784. https://doi.org/10.1016/j.semcdb.2012.07.002 (2012).
doi: 10.1016/j.semcdb.2012.07.002
pubmed: 22898666
pmcid: 3489012
Yang, Z. et al. miR-155-dependent regulation of mammalian sterile 20-like kinase 2 (MST2) coordinates inflammation, oxidative stress and proliferation in vascular smooth muscle cells. Biochim. Biophys. Acta 1852, 1477–1489. https://doi.org/10.1016/j.bbadis.2015.04.012 (2015).
doi: 10.1016/j.bbadis.2015.04.012
pubmed: 25892184
Thery, F. et al. Ring finger protein 213 assembles into a sensor for ISGylated proteins with antimicrobial activity. Nat. Commun. https://doi.org/10.1038/s41467-021-26061-w (2021).
doi: 10.1038/s41467-021-26061-w
pubmed: 34599178
pmcid: 8486878
Wright, A. F. et al. Oestrogen receptor alpha in pulmonary hypertension. Cardiovasc. Res. 106, 206–216. https://doi.org/10.1093/cvr/cvv106 (2015).
doi: 10.1093/cvr/cvv106
pubmed: 25765937
pmcid: 4615797
Ortmann, J. et al. Estrogen receptor-alpha but not -beta or GPER inhibits high glucose-induced human VSMC proliferation: Potential role of ROS and ERK. J. Clin. Endocrinol. Metab. 96, 220–228. https://doi.org/10.1210/jc.2010-0943 (2011).
doi: 10.1210/jc.2010-0943
pubmed: 20962025
Jin, F. & Duan, C. Identification of immune-infiltrated hub genes as potential biomarkers of moyamoya disease by bioinformatics analysis. Orphanet J. Rare Dis. https://doi.org/10.1186/s13023-022-02238-4 (2022).
doi: 10.1186/s13023-022-02238-4
pubmed: 36503528
pmcid: 9743713
Cao, L. et al. Bioinformatics analysis reveals the landscape of immune cell infiltration and novel immune-related biomarkers in moyamoya disease. Front. Genet. https://doi.org/10.3389/fgene.2023.1101612 (2023).
doi: 10.3389/fgene.2023.1101612
pubmed: 38274110
pmcid: 10751322
Huang, D., Qi, H., Yang, H. & Chen, M. Plasma exosomal microRNAs are non-invasive biomarkers of moyamoya disease: A pilot study. Clinics (Sao Paulo) https://doi.org/10.1016/j.clinsp.2023.100247 (2023).
doi: 10.1016/j.clinsp.2023.100247
pubmed: 37879248
Kamelamela, N., Zalesne, M., Morimoto, J., Robbat, A. & Wolfe, B. E. Indigo- and indirubin-producing strains of proteus and psychrobacter are associated with purple rind defect in a surface-ripened cheese. Food Microbiol. 76, 543–552. https://doi.org/10.1016/j.fm.2018.07.011 (2018).
doi: 10.1016/j.fm.2018.07.011
pubmed: 30166186
Adachi, J. et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 276, 31475–31478. https://doi.org/10.1074/jbc.C100238200 (2001).
doi: 10.1074/jbc.C100238200
pubmed: 11425848
Alex, D., Lam, I. K., Lin, Z. & Lee, S. M. Indirubin shows anti-angiogenic activity in an in vivo zebrafish model and an in vitro HUVEC model. J. Ethnopharmacol. 131, 242–247. https://doi.org/10.1016/j.jep.2010.05.016 (2010).
doi: 10.1016/j.jep.2010.05.016
pubmed: 20488232
Blazevic, T. et al. Indirubin-3’-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc. Res. 101, 522–532. https://doi.org/10.1093/cvr/cvt339 (2014).
doi: 10.1093/cvr/cvt339
pubmed: 24368834